Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: J Thromb Thrombolysis

Search In Journal Title:

Abbravation: Journal of Thrombosis and Thrombolysis

Search In Journal Abbravation:

Publisher

Springer US

Search In Publisher:

DOI

10.1016/j.aap.2015.06.014

Search In DOI:

ISSN

1573-742X

Search In ISSN:
Search In Title Of Papers:

Anticoagulation in the management of venous thromb

Authors: Michael B Streiff
Publish Date: 2011/02/18
Volume: 31, Issue: 3, Pages: 282-294
PDF Link

Abstract

Cancer is associated with a four to sevenfold increased risk of venous thromboembolism VTE This risk is influenced by the site and extent of cancer and its treatment Despite its availability effective VTE prophylaxis is used in less than 50 of oncology patients Pharmacologic VTE prophylaxis should be administered to all hospitalized medical and surgical oncology patients for the duration of their hospitalization or up to 10–14 days whichever is longer Extended duration up to 4 weeks postoperation VTE prophylaxis is recommended for highrisk surgical oncology patients Routine use of prophylaxis in ambulatory medical oncology patients awaits prospective testing of VTE risk assessment models Routine prophylactic dose anticoagulation to prevent central venous catheter CVC thrombosis is ineffective and not indicated Low molecular weight heparin is the first line choice for acute and chronic therapy of VTE in cancer patients Therapy should continue for at least 3 months or the duration of the malignancy whichever is longer Anticoagulation is indicated for at least 3 months or the duration of the catheter for CVC thrombosis Preliminary data indicate that some cancer patients with pulmonary embolism may be managed as outpatients Prospective validation of these studies and testing of current risk assessment strategies in oncology patients is warranted Management of recurrent VTE and unsuspected VTE in the cancer patient are also reviewed

Keywords:

References

.
Search In Abstract Of Papers:
Other Papers In This Journal:
  1. The inhibition in tumor necrosis factor-α-induced attenuation in endothelial thrombomodulin expression by carvedilol is mediated by nuclear factor-κB and reactive oxygen species
  2. Comparison of platelet inhibition by prasugrel versus ticagrelor over time in patients with acute myocardial infarction
  3. Does supervised exercise after deep venous thrombosis improve recanalization of occluded vein segments? A randomized study
  4. Association between sleep condition and arterial stiffness in Chinese adult with nonalcoholic fatty liver disease
  5. In vitro shear stress modulates antithrombogenic potentials of human endothelial progenitor cells
  6. Polymorphism in the methylenetetrahydrofolate reductase (C677T) gene and homocysteine levels: a comparison in Brazilian patients with coronary arterial disease, ischemic stroke and peripheral arterial obstructive disease
  7. Role of thrombophilia testing: con
  8. Venous thromboembolism and cancer: a systematic review
  9. Dabigatran-associated subdural hemorrhage: using thromboelastography (TEG ® ) to guide decision-making
  10. Proceedings of the 10th National Conference on Anticoagulant Therapy
  11. Comparative efficacy of in vitro and in vivo metabolized aspirin in the DeBakey ventricular assist device
  12. The relationship between gender and age with monocyte tissue factor expression
  13. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability
  14. A comparison of direct thrombin inhibitors in the treatment of heparin-induced thrombocytopenia: a single institution experience
  15. US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins
  16. Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study
  17. Abnormal asymmetric dimethylarginine/nitric oxide balance in patients with documented coronary artery disease: relation to renal function and homocysteine
  18. Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention
  19. Cardiovascular risk factors and outcome in patients with retinal vein occlusion
  20. Impact of type of thrombolytic agent on in-hospital outcomes in ST-segment elevation myocardial infarction patients in the Middle East
  21. Prognostic significance of multidetector computed tomography in normotensive patients with pulmonary embolism: rationale, methodology and reproducibility for the PROTECT study
  22. Increased platelet activation in patients with slow coronary flow
  23. Biomarkers of deep venous thrombosis
  24. Thromboembolic complications following a first isolated episode of superficial vein thrombosis: a cross-sectional retrospective study
  25. The impact of factor Xa inhibition on axial dependent arterial thrombus formation triggered by a tissue factor rich surface
  26. New oral Xa and IIa inhibitors: updates on clinical trial results
  27. Spontaneous coronary thrombosis following thrombolytic therapy for acute cardiovascular accident and stroke: a case study
  28. Anti-coagulant activity of a metalloprotease: further characterization from the Indian cobra ( Naja naja ) venom
  29. Evaluation of the Alere D-dimer test for point of care testing
  30. Strategies and outcomes of periprocedural bridging therapy with low-molecular-weight heparin in patients with mechanical heart valves
  31. Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial
  32. Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism
  33. Methylenetetrahydrofolate reductase (MTHFR) C677T genetic polymorphism and late infarct-related coronary artery patency after thrombolysis
  34. Are surgical patients at risk of venous thromboembolism currently meeting the Surgical Care Improvement Project performance measure for appropriate and timely prophylaxis?
  35. Evaluation of von Willebrand factor and ADAMTS-13 antigen and activity levels in sickle cell disease patients in Kuwait
Search Result: